Tumor-treating pharmaceutical composition

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11925639
APP PUB NO 20190388420A1
SERIAL NO

16465277

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • EISAI R & D MANAGEMENT CO., LTD.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hori, Yusaku Tokyo, JP 6 14
Kamiyama, Hiroshi Tsukuba, JP 36 440
Matsuki, Masahiro Tsukuba, JP 4 6
Ozawa, Yoichi Tsukuba, JP 87 2012
Yamada, Kazuhiko Tsukuba, JP 64 750

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Sep 12, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 12, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 12, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00